摘要
目的:筛选治疗性乙肝疫苗的候选抗原。方法:分别用国产CHO乙肝表面抗原和酵母乙肝表面抗原结合DCChol脂质体佐剂免疫BALB/c小鼠,1周后检测其脾细胞产生的IL2和IFNγ的水平。ELISPOT法评价铝佐剂和DCChol脂质体佐剂结合HBsAg促小鼠细胞免疫反应水平。结果:酵母乙肝表面抗原结合DCChol脂质体所诱导的IL2和IFNγ的水平分别为CHO乙肝表面抗原结合DCChol脂质体的20倍和119倍。酵母乙肝表面抗原结合DCChol脂质体所诱导的IL4和IFNγ的斑点数分别为酵母乙肝表面抗原结合铝佐剂的2.8倍和46.3倍。结论:就DCChol脂质体佐剂而言,酵母表达的乙肝表面抗原细胞免疫原性强,是适合用于治疗性乙肝疫苗的候选疫苗。
Objective： To screen candidate antigen for therapeutic HBV vaccine with a novel adjuvant DC-Chol. Methods： BALB/c mice were injected with DC-Chol liposome and HBsAg prepared from CHO and Yeast respectively. One week later, IL-4, IL-2, IFN-γwere measured by ELISA or ELISPOT. Results： The levels of IL-2, IFN-γof HBsAg from Yeast with DC-Chol liposome were 20 and 119 times higher respectively than those of HBsAg from CHO with DC-Chol liposome. ELISPOT assay showed that the counts of spot-forming cells of IL-4 and IFN-γf HBsAg from Yeast with DC-Chol liposome were 2.8 and 46.3 times higher respectively than those of HBsAg from Yeast with A1 （OH） 3. Conclusion ： HBsAg prepared from Yeast together with DC-Chol liposome may be an appropriate candidate for therapeutic HBV vaccine .
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2006年第3期22-25,共4页
China Biotechnology
基金
广东省科技攻关项目(2003C31205)
